EXPLANATORY NOTE: [***] INDICATES THE PORTION OF THIS EXHIBIT THAT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. CO-ORDINATION AGREEMENT (“Agreement”)Co-Ordination Agreement • March 31st, 2023 • AIM ImmunoTech Inc. • Biological products, (no disgnostic substances)
● AIM ImmunoTech is an immune-pharma company focused on the research and development of therapeutics to treat multiple types of cancer. AIM ImmunoTech’s flagship product is Rintatolimod.
